Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CRL · NYSE · United States · Services-Commercial Physical & Biological Research
In shortCHARLES RIVER LABORATORIES INTERNATIONAL, INC. is loss-making, generates cash and carries moderate debt, with revenue stable (−0.9% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 0.6% | 19/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -3.6% | 6/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -4.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 0.4% | 2/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.29× | 41/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.68× | 74/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 4.49× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 0.24× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.81 | 18/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 12.9% | 72/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 9.7% | 75/100 |
| Operating margin volatility | 7.3% | 43/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 0.3% | 18/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 |
| Selling, general & admin | 620 | 665 | 748 | 751 | 743 |
| Operating income | 590 | 651 | 617 | 227 | 25 |
| Interest expense | 74 | 59 | 137 | 126 | 107 |
| Pre-tax income | 481 | 623 | 581 | 93 | (100) |
| Income tax | 82 | 130 | 101 | 68 | 43 |
| Net income | 391 | 486 | 475 | 22 | (144) |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | −$2.91 |
| Diluted shares (millions) | 51 | 51 | 51 | 52 | 50 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. are included in the Investor plan. Try free for 7 days →
1.81 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 27, 2026 · Data updated Aug 5, 2026